Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

The present, updated document describes the fourth iteration of recommendations for the
hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Cholangiocarcinoma (CCA) is the second most common primary malignancy. Although it is
more common in Asia, its incidence in Europe and North America has significantly increased …

One of the key strategies to improve the prognosis of HCC, beside prevention, is to diagnose
the tumor in early stages, when the patient is asymptomatic and the liver function is …

Cholangiocarcinoma (CCA) is a heterogeneous group of tumours, derived from cells of the
biliary tree, which represent the second most frequent primary liver tumour. According to the …

Cholangiocarcinoma represents a diverse group of epithelial cancers united by late
diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are …

Background & Aims The use of contrast enhanced ultrasound (CEUS) for the diagnosis of
hepatocellular carcinoma (HCC) in cirrhosis was questioned because of the risk of a false …